Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.77 |
| ▸ | TNF | P01375 | 3/20 | 0.77 |
| ▸ | IL1B | P01584 | 3/20 | 0.77 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avadomide SCHEMBL15945430 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15945429 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL31723020 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442251 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442252 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15945433 | 0.89 | DDB1 (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL634577 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL282749 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442249 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220098128-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-2943201-B2 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES | DEUTERX LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9540340-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140228382-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | CRBN 2228/4885DDB1 781/4885IKZF3 14/4885 |
| US-20140228382-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CRBN 1871/4885DDB1 1162/4885IKZF3 9/4885 |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CRBN 1871/4885DDB1 1162/4885IKZF3 9/4885 |
| US-20220098128-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL15, CXCR5 | CRBN 2228/4885DDB1 781/4885IKZF3 14/4885 |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | CRBN 1871/4885DDB1 1162/4885IKZF3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.